The biological consequences of histone deacetylase inhibition include reversion of transformed cell morphology and inhibition of cell proliferation by induction of G1/S and G2/M phase cell cycle arrest, differentiation, and/or apoptosis. 4) HDAC inhibitors e.g. trichostatin A, suberoylanilide hydroxamic acid (SAHA), PXD-101, LBH-589, scriptaid, oxamflatin or MS-275 selectively induce cellular differentiation, growth arrest and apoptosis in a broad spectrum of tumor cells. Moreover, HDAC inhibitors have been implicated in the inhibition of angiogenesis, an effect contributing to tumor regression. [5] [6] [7] [8] [9] [10] Vorinostat (SAHA) has low solubility and permeability classification (class IV) according to the Biopharmaceutics Classification System (BCS). It was a challenging force to find another molecule in the HDAC inhibitor class, which would have favorable, physicochemical, PK and PD attributes superior to that of SAHA. SB639 ( Fig. 1 ) is a promising novel small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other very active anti-cancer agents. SB639 is chemically N-hydroxy-3-[2-phenethyl1-1-(2-pyrrolidin-1-yl-ethyl)-1H-benzimidazol-5-yl]-acrylamide. SB639 is a potent, specific, and reversible histone deacetylase inhibitor at low nanomolar concentrations across the tested human cancer cell lines. As a part of the preclinical profiling of SB639, the present investigation was undertaken to characterize the in vitro CYP P450 stability, permeability, pharmacokinetics and oral bioavailability of SB639 in mice and rats and compared to the recently FDA approved drug Vorinostat (SAHA).
MATERIALS AND METHODS
Chemicals and Reagents SB639 and SAHA was synthesized by medicinal chemistry group, S*BIO Pte Ltd., and
In Vitro Phase I Cytochrome P450 Metabolism, Permeability and Pharmacokinetics of SB639, a Novel Histone Deacetylase Inhibitor in Preclinical Species were characterized using chromatographic and spectral techniques. Purity was found to be more than 99%. Methanol (HPLC grade) was obtained from JT Baker, methyl-tert-butyl ether (ACS grade) from Acros Singapore, Verapamil was purchased from Sigma-Aldrich, U.S.A., formic acid (ACS grade) was from Merck, U.S.A., and the internal standard was carbamazepine (Sigma-Aldrich, U.S.A.). Naïve mouse and rat plasma were harvested from mice and rats purchased from National University of Singapore Centre for Animal Resources (NUS-CARE, Singapore).
All other reagents used were of laboratory reagent grade and were used without further purification. All aqueous solutions for HPLC and LC-MS/MS mobile phase were prepared in Milli Q (Millipore, Milford, MA, U.S.A.) grade water. Pooled liver microsomes of human, mouse, Beagle dog liver microsomes were obtained from BD Gentest U.S.A., whereas male Wistar rat liver microsomes were prepared in-house.
Animals Female Balb/c nude mice weighing 18-22 g (8-10 weeks of age) were purchased from Animal Resources Centre (ARC), Western Australia. Male Wistar rats weighing 230-250 g (6-8 weeks) were bred in BioArc Research Solutions, India. They were housed under standard conditions and had ad libitum access to water and standard laboratory rodent diet. All studies performed were approved by Institutional Animal Care and Use Committee (IACUC) of National university of Singapore and India Analytical Procedure For samples generated in the in vitro and in vivo studies, quantitative analysis of SB639 was conducted using LC-MS/MS. The liquid chromatographic system consisted of a Waters HT Alliance 2795 with a temperature control autosampler. The detector was a Micromass (Waters Corporation) Quattro Micro mass spectrometer. The analytical column C 18 Luna (2ϫ50 mm, 5 mm, Phenomenex U.S.A.) was used for the chromatographic separation. The HPLC column was set at 40°C. The mobile phase consisted of 60% methanol and 40% water with 0.1% formic acid, and was delivered at a flow rate of 0.3 ml/min. The sample volume injected was 40 ml and the autosampler was set at 4°C. The analysis time was 3-5 min. The longer run time was necessary to minimize ion suppression that decreased sensitivity of the assay using a shorter run time. Electrospray ionization in the positive mode was used in the sample introduction and detection was operated in the multiple reactionmonitoring (MRM) modes was set at m/z 405 to m/z 98. The source temperature was set at 120°C, the Collision energy was set at 22 eV and Cone voltage applied was 30 V.
SB639 standard curve was linear (r 2 ϭ0.99) over the range of 1-2000 ng/ml in rat and mouse plasma. The accuracy and precision of the QC samples were within 15% of deviation and 15% relative standard deviation, respectively.
In Vitro Metabolic Stability Studies In vitro experiments were conducted according to Obach RS et al., 1999 11) , in mouse, rat, dog and human hepatic microsomal fractions. The incubation mixtures of SB639 with liver microsomes (mice, rat, dog and human) contained the following at the indicated final concentrations (final volume of 1500 ml, 100 mM potassium phosphate buffer (pH 7.4), microsomes (1 mg/ml) and 1 mM of NADPH regenerating system. The mixtures were pre-incubated at 37°C for 10 min.
11) The metabolism reaction (in triplicate) was initiated by addition of 5 mM SB639 to the incubation mixture. At times 5, 15, 30, 45 and 60 min, 50 ml aliquot of the reaction mixture was quenched using 100 ml of a stop solution containing 20% DMSO/acetonitrile. The samples were centrifuged at 4°C for 15 min at 2000 rpm. The supernatant was transferred to a 96-well plate for analysis using a generic LC-MS method. The microsomal activity was monitored using verapamil as positive control.
Caco-2 Permeability Assay Caco-2 human intestinal epithelial cells were plated in Transwell ® dual chamber plates. The permeability studies were conducted with the monolayers cultured for 21 to 28 d in culture. The integrity of each Caco-2 cell monolayer was certified by transepithelial electrical resistance (TEER) test (pre-experiment) and Lucifer Yellow flux (post-experiment). The concentration of SB639 used in the assay was 10 mM (10 mM stock solution made in DMSO). The uni-directional permeability studies were initiated by adding an appropriate volume of buffer (pHϭ7.4) containing SB639 to the apical (apical to basolateral transport) side of the monolayer (nϭ2). Samples were taken from both the apical and basolateral compartment at the end of a 2 h incubation period and the concentrations of SB639 were analyzed by LC/MS/MS assay. Permeability coefficient (P app ) was expressed as centimeter per second. SAHA's permeability value was taken from the New Drug Application 12) (NDA). , then fed 4 h after dosing. Blood (0.25 ml) was collected from an indwelling superior vena cava cannula over K 3 EDTA over the 0-24 h post-dose period. Plasma samples from mice and rats were extracted with methyl-tert-butyl ether (MTBE) containing an internal standard, centrifuged and analysed for SB639 by LC-MS/MS.
Pharmacokinetics Studies for SB639 in Mice and Rats
Pharmacokinetic Data Analysis Non-compartmental pharmacokinetic parameters (Gibaldi and Perrier 1982) 13) are calculated using WinNolin 5.0.1 software (Pharsight, Mountain View, CA, U.S.A.). Absolute oral bioavailability (F) was calculated using the relationship,
Statistics Statistical analysis (ANOVA) was performed using Graph pad prism version 4., U.S.A. and the significance level adopted for all statistical comparisons was pϽ0.05.
RESULTS

In Vitro Metabolic Stability Studies
Metabolic stability (t 1/2 ) of SB639 in different species liver microsomes is presented in Table 1 . It can be graded as humanϳdogϾratϾ mouse. The metabolic stability of SB639 was comparable with that of SAHA in human and dog liver microsomes.
Caco-2 Permeability Assay The rate of transport (P app A to B ) of SB639 in Caco-2 cells was 3.01 · 10 Ϫ6 cm/s at 10 mM, which was two times higher than that reported 13) for SAHA (1.70 · 10 Ϫ6 cm/s).
Pharmacokinetics Studies for SB639 in Mice and Rats
The mean oral and i.v. pharmacokinetic parameters for SB639 with comparison of SAHA in mice are summarized in Table 2 . Following i.v. administration, plasma concentrations of SB639 and SAHA decreased bi-exponentially and elimination half-life was found to be 1.67 h and 0.38 h, respectively. Systemic exposure, clearance and volume of distribution of SB639 were 634 ng · h/ml, 15.8 l/h/kg and 38.1 l/kg and for SAHA the values were 1486 ng · h/ml, 6.73 l/h/kg and 3.7 l/kg, respectively. After oral administration, absorption of SB639 from mouse gastrointestinal tract was rapid; SB639 was detected in plasma from the first blood sampling point (0.17 h) and the maximum plasma concentrations attained at 0.17 h at the tested dose. The PK parameters for SB639 and SAHA were very much comparable except the terminal halflife for SB639 was longer (1.64 h). Absolute oral bioavailability for SB639 was found to be 13% at 50 mg/kg oral dose which was better than SAHA (8%).
14)
The mean oral pharmacokinetic parameters for SB639 and SAHA in Wistar rats are summarized in Table 3 . Following i.v. administration of SB639 and SAHA to rats, the plasma concentrations declined in a bi-exponential fashion with a terminal half-life of 1.12 h and 0.64 h respectively. Systemic exposure, clearance and volume of distribution of SB639 were 525 ng · h/ml, 3.84 l/h/kg and 3.67 l/kg and for SAHA the values were 278 ng · h/ml, 8.04 l/h/kg and 7.5 l/kg, respectively. After oral administration, SB639 reached maximum plasma levels within 0.5 h. Absolute oral bioavailability of SB639 at 5 mg/kg was found to be 10.5% and was more than SAHA (6.9%).
DISCUSSION
Development of lead candidates of novel programs in anticancer therapy area necessitates a thorough exploration and understanding of pharmacokinetic disposition. This is important since the in vivo PK behavior and PK-PD correlation can act as surrogates for the clinical effectiveness of the compounds. In the hit to lead optimization of molecules in the HDAC program, at the very minimal, the PK profile had to be either equal to or better than those attributed to SAHA, PXD101, LBH589 or other HDAC inhibitors. It was a challenging force to find another molecule in the HDAC inhibitor class, which would have PK and PD attributes superior to that of lead HDAC inhibitors.
The in vitro metabolism data suggested that SB639 was unstable in mouse and rat liver microsomes, however, stable in human and dog liver microsomes. SB639 also exhibited favorable physicochemical properties over SAHA with clogP of 3.9 and 1.8, aqueous solubility of Ͼ120 mg/ml and 100 mg/ml respectively. 13) SB639 in vitro anti-cell proliferation activity combined with its superior physicochemical properties was anticipated to yield good PK and efficacy (not shown). The oral bioavailability of SB639 was in the vicinity of 13% in both rodent species and was improved in comparison with other HDAC inhibitors.
14) The 2-fold improvement in t 1/2 for SB639 compared to SAHA in both species might offer better advantage for our compound as an oral drug. In addition the levels of SB639 remained above LOQ concentrations up to 8 h of post dosing in both the species and routes compared to 4 h for SAHA. The superior potency, solubility, permeability and pharmacokinetic properties of SB639 compared to the recently FDA approved drug Vorinostat (SAHA) in the preclinical setting makes it a potential clinical candidate. 
